Can low‑dose aspirin (acetylsalicylic acid) be started for pregnancy‑induced hypertension in a patient with a subchorionic hemorrhage?

Can Aspirin Be Started for Pregnancy-Induced Hypertension in a Patient with Subchorionic Hemorrhage?

Yes, low-dose aspirin can be initiated for pregnancy-induced hypertension even in the presence of subchorionic hemorrhage, as aspirin does not increase bleeding complications and the maternal mortality/morbidity benefits of preventing severe preeclampsia outweigh theoretical bleeding concerns. 1, 2

Evidence Supporting Aspirin Safety in Bleeding Contexts

Low-dose aspirin (75-162 mg daily) does not increase the risk of placental abruption, postpartum hemorrhage, fetal intracranial bleeding, or perinatal mortality in pregnant women. 1, 2 This safety profile has been established across multiple large randomized controlled trials and meta-analyses. 1

While one 2023 meta-analysis suggested a modest increase in postpartum hemorrhage risk (OR 1.20), the absolute increase in blood loss was clinically insignificant at only 12.85 mL, and this finding must be weighed against the substantial reduction in severe preeclampsia and its life-threatening complications. 3

Subchorionic Hemorrhage-Specific Considerations

Subchorionic hemorrhage in the second and third trimesters is associated with adverse outcomes including preterm birth, fetal growth restriction, and preterm prelabor rupture of membranes—but anticoagulation therapy (not aspirin) is the only known risk factor for subchorionic hemorrhage. 4 This distinction is critical: therapeutic anticoagulation increases bleeding risk, whereas low-dose aspirin's antiplatelet effect does not appear to worsen subchorionic hemorrhage outcomes. 4

There is no evidence that aspirin worsens subchorionic hemorrhage or increases its complications. The absence of aspirin from the list of risk factors for subchorionic hemorrhage in comprehensive reviews suggests it is not contraindicated in this setting. 4

Dosing and Timing Recommendations

For pregnancy-induced hypertension (which includes chronic hypertension with or without superimposed preeclampsia):

• Initiate aspirin at 100-150 mg daily rather than the standard 81 mg dose, as women with chronic hypertension show no benefit from 81 mg aspirin and may require higher dosing. 5, 1
• Start between 12-16 weeks of gestation if possible, though later initiation still provides benefit through aspirin's anti-inflammatory and endothelial-protective mechanisms. 1, 2
• Continue daily until delivery without stopping at 36 weeks, as preeclampsia risk persists through the peripartum period. 1

The evidence is particularly strong that standard 81 mg aspirin does not prevent superimposed preeclampsia in women with chronic hypertension (34.3% vs 35.5%, p=0.79), and severe features actually increased in one study. 5 This supports using higher doses (100-150 mg) in this population. 1

Clinical Decision Algorithm

Step 1: Assess subchorionic hemorrhage stability

• If the hemorrhage is stable (not actively expanding, no ongoing vaginal bleeding requiring transfusion), proceed with aspirin initiation. 4
• If massive ongoing hemorrhage requiring blood transfusion, defer aspirin until bleeding stabilizes, but this scenario is rare. 4

Step 2: Initiate aspirin at appropriate dose

• Use 100-150 mg daily (not 81 mg) for pregnancy-induced hypertension. 1
• Start immediately if between 12-28 weeks; benefit persists even with later initiation. 1, 2

Step 3: Monitor for both conditions

• Serial growth ultrasounds and umbilical artery Doppler studies for the subchorionic hemorrhage. 4
• Blood pressure monitoring and proteinuria assessment for preeclampsia progression. 5

Critical Pitfalls to Avoid

Do not withhold aspirin based solely on the presence of subchorionic hemorrhage. The maternal mortality risk from severe preeclampsia (eclamptic seizures, stroke, HELLP syndrome, placental abruption) far exceeds any theoretical bleeding risk from low-dose aspirin. 1, 2

Do not use 81 mg aspirin in women with chronic hypertension or pregnancy-induced hypertension, as this dose has been proven ineffective in this population. 5, 1 The higher 100-150 mg dose is supported by international guidelines including FIGO and the American Diabetes Association. 1

Do not confuse low-dose aspirin (75-162 mg) with high-dose aspirin (>300 mg). The FDA warning about aspirin in the third trimester refers to high doses, not prophylactic low doses. 1, 6

Do not stop aspirin at 36 weeks "to be safe" before delivery. This removes protection during the highest-risk period without evidence-based justification. 1

Balancing Risks and Benefits

The key clinical judgment is recognizing that severe preeclampsia causes maternal death and stroke, while low-dose aspirin causes at most a 13 mL increase in postpartum blood loss—a clinically negligible amount that does not require transfusion. 3, 1

In women with pregnancy-induced hypertension, aspirin reduces preeclampsia by 24%, preterm birth by 14%, and intrauterine growth restriction by 20%. 1, 2 These benefits in reducing morbidity and mortality clearly outweigh the presence of a subchorionic hemorrhage, which is not worsened by aspirin. 4, 1